GlassScriptPhysician profile
Jessica Watari
NPI 1801324793
$3,740.13
in general payments reported to CMS, 2019-2025
14 companies · $955 in 2025
The $955 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.75 · 2022: $892 · 2023: $339 · 2024: $1,532 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,985 · Travel and Lodging: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.18 |
| Travel and Lodging | $841.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,276.46 | 2022-2025 | Minimed 780g |
| Novo Nordisk INC | $817.15 | 2020-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $631.76 | 2024-2025 | Freestyle Libre 3 |
| Amgen INC. | $324.80 | 2022-2025 | Tepezza, Repatha |
| Xeris Pharmaceuticals, INC. | $238.42 | 2022-2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $105.53 | 2023 | |
| Corcept Therapeutics | $88.08 | 2024 | Korlym |
| Alexion Pharmaceuticals, INC. | $58.79 | 2025 | Strensiq |
| Amarin Pharma, INC. | $56.31 | 2022 | |
| Lilly USA, LLC | $44.42 | 2023-2024 | Jardiance, Baqsimi, Lyumjev |
| Astrazeneca Pharmaceuticals LP | $32.43 | 2022-2023 | Farxiga |
| Radius Health, INC. | $23.24 | 2022 | |
| Tandem Diabetes Care, INC. | $21.51 | 2022 | |
| Embecta Corp. | $21.23 | 2023 | Bd Nano 2nd Gen Pen Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Watari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.